Epicrispr Biotechnologies Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 43

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $8M

  • Investors
  • 15

Epicrispr Biotechnologies General Information

Description

Developer of a gene expression modulation platform designed to treat complex diseases. The company develops a gene expression modulation System (GEMS) platform that combines epigenomic modulators to control gene expression, enabling healthcare professionals to use customized therapies for specific disease indications.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 7000 Shoreline Court
  • Suite 100
  • San Francisco, CA 94080
  • United States
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Biotechnology
Vertical(s)
Corporate Office
  • 7000 Shoreline Court
  • Suite 100
  • San Francisco, CA 94080
  • United States

Epicrispr Biotechnologies Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Epicrispr Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 19-Oct-2026 $8M Completed Clinical Trials - General
3. Later Stage VC (Series C) 10-Aug-2026 Completed Clinical Trials - General
2. Later Stage VC (Series B) 26-Mar-2025 $75.5M $131M Completed Clinical Trials - General
1. Early Stage VC (Series A) 12-Jul-2022 $55M $55M Completed Clinical Trials - General
To view Epicrispr Biotechnologies’s complete valuation and funding history, request access »

Epicrispr Biotechnologies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2
Series A1
Seed 25,510,200 $0.000010 6% $0.1 $0.1 1x $0.1 19.07%
To view Epicrispr Biotechnologies’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Epicrispr Biotechnologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a gene expression modulation platform designed to treat complex diseases. The company develops a gene expre
Discovery Tools (Healthcare)
San Francisco, CA
43 As of 2026

Cambridge, MA
 

Toronto, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Epicrispr Biotechnologies Competitors (38)

One of Epicrispr Biotechnologies’s 38 competitors is Arbor Biotechnologies, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arbor Biotechnologies Venture Capital-Backed Cambridge, MA
Deep Genomics Venture Capital-Backed Toronto, Canada
Metagenomi Therapeutics Formerly VC-backed Emeryville, CA
EdiGene Venture Capital-Backed Beijing, China
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
You’re viewing 5 of 38 competitors. Get the full list »

Epicrispr Biotechnologies Patents

Epicrispr Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025254779-A1 Engineered epigenetic effectors Pending 06-Jun-2024
EP-4774383-A1 Engineered cas12 polypeptides, compositions, and methods of use thereof Pending 06-Sep-2023
WO-2025054029-A1 Engineered cas12 polypeptides, compositions, and methods of use thereof Inactive 06-Sep-2023
WO-2025019273-A1 Engineered nucleases and guide rna spacer sequences therefor, and compositions, and methods of use thereof Inactive 14-Jul-2023
EP-4713342-A2 Systems and methods for regulating target genes Pending 17-May-2023 C12N9/226
To view Epicrispr Biotechnologies’s complete patent history, request access »

Epicrispr Biotechnologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Epicrispr Biotechnologies Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
California Institute for Regenerative Medicine Government
Aberdeen Investments (Scotland) Asset Manager Minority
abrdn Healthcare Investors Hedge Fund Minority
Angelini Ventures Corporate Venture Capital Minority
Cormorant Asset Management PE/Buyout Minority
You’re viewing 5 of 15 investors. Get the full list »

Epicrispr Biotechnologies FAQs

  • When was Epicrispr Biotechnologies founded?

    Epicrispr Biotechnologies was founded in 2018.

  • Where is Epicrispr Biotechnologies headquartered?

    Epicrispr Biotechnologies is headquartered in San Francisco, CA.

  • What is the size of Epicrispr Biotechnologies?

    Epicrispr Biotechnologies has 43 total employees.

  • What industry is Epicrispr Biotechnologies in?

    Epicrispr Biotechnologies’s primary industry is Discovery Tools (Healthcare).

  • Is Epicrispr Biotechnologies a private or public company?

    Epicrispr Biotechnologies is a Private company.

  • What is Epicrispr Biotechnologies’s current revenue?

    The current revenue for Epicrispr Biotechnologies is .

  • How much funding has Epicrispr Biotechnologies raised over time?

    Epicrispr Biotechnologies has raised $221M.

  • Who are Epicrispr Biotechnologies’s investors?

    California Institute for Regenerative Medicine, Aberdeen Investments (Scotland), abrdn Healthcare Investors, Angelini Ventures, and Cormorant Asset Management are 5 of 15 investors who have invested in Epicrispr Biotechnologies.

  • Who are Epicrispr Biotechnologies’s competitors?

    Arbor Biotechnologies, Deep Genomics, Metagenomi Therapeutics, EdiGene, and CRISPR Therapeutics are some of the 38 competitors of Epicrispr Biotechnologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process